about
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosingThe human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic coreDrug methylation in cancer therapy: lessons from the TPMT polymorphismPharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprineAssociation of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapyDisequilibrium mapping of a quantitative-trait locus in an expanding population.Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes.Review and meta-analysis of systematic searches for uniparental disomy (UPD) other than UPD 15.Murine pharmacogenomics: using the mouse to understand the genetics of drug therapy.Pharmacogenomics: marshalling the human genome to individualise drug therapyAzathioprine: current status and future considerations.Cancer pharmacogenomics: SNPs, chips, and the individual patient.Development and implementation of a pharmacist-managed clinical pharmacogenetics service.Watson and Crick 50 years on. From double helix to pharmacogenomics.Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatmentJapanese single nucleotide polymorphism database for 267 possible drug-related genes.Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.Pharmacogenetics and diseases of the colon.ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogeneticsGenetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.Pharmacogenomics of pediatric acute lymphoblastic leukemia.Pharmacogenetics in dermatology: a patient-centered update.Thiopurine metabolite testing in inflammatory bowel disease.cDNA microarray analysis of vascular gene expression after nitric oxide donor infusions in rats: implications for nitrate tolerance mechanisms.Nanomedicine Faces Barriers.Influence of thiopurine methyltransferase gene polymorphism on Egyptian children with acute lymphoblastic leukaemia.
P2860
Q24632749-D531F2FD-A041-4B34-9A51-2736AC464FAEQ27677053-FF023E32-2DC1-4E6A-9901-EAABB2059464Q28212325-13367813-2C6B-459C-BF78-2B8B3BB87198Q33380531-9C4E8614-2035-4420-B40F-DAE8189CFD07Q34323258-8FA92611-0A9A-496B-93F3-C6F6F787C553Q34389867-58B7F1D5-A357-4FF8-B7A2-8285DAFCB11DQ34612932-79F193B1-80B6-4B5A-B57B-2CCFC1020388Q34811053-EFB42D85-AB51-41EB-A4B5-3BEB0BBC31ECQ35000912-090681C4-0DE8-4C0C-8B17-C1DEEF766D4CQ35090217-D25346BA-69DB-4FF0-AC43-71E57BBEFBA5Q35130911-6E0756E3-CF8D-4ACB-85F5-87230C2FA980Q35553873-3B27EBA1-5636-42FC-B503-C456D00EE613Q35586019-543B1CF8-84D6-40E5-915E-2470382BD4D8Q35630029-296A9829-0F90-4240-9ACC-E66CEBED656CQ35848092-09824532-30E2-40BE-B01F-8277C03E0BE0Q36347893-5E10729E-F654-4B19-8969-6932FC9B7D87Q36402208-87AF7498-3300-4118-9E1F-522C5CAF2C65Q36404764-6CC24255-EE38-40D7-9455-A838F2638BBDQ37308142-3ED649A3-50D3-4A9F-8E03-201200E85660Q37388537-EA5ABCBA-58C7-4DE9-81F3-593C1C667AF6Q37658863-D8804B69-A198-4852-944C-5D8ECBF27592Q37739432-CF10A653-046C-4DFC-A627-629A8D6839A0Q38115822-1D4EE94C-99AE-4E98-8269-A0FB840E3AEDQ38618602-65DA2F28-3864-4965-9C05-B94B5A796B54Q41892733-48366B4A-30AB-487D-8955-24FC21543E66Q46181824-CDEF324E-AE23-4461-8EF2-710766645580Q50101889-D5E6D9BB-B5CE-473B-A8FD-C7F23B3ADD1B
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Pharmacogenetics of cancer therapy: getting personal
@ast
Pharmacogenetics of cancer therapy: getting personal
@en
Pharmacogenetics of cancer therapy: getting personal
@nl
type
label
Pharmacogenetics of cancer therapy: getting personal
@ast
Pharmacogenetics of cancer therapy: getting personal
@en
Pharmacogenetics of cancer therapy: getting personal
@nl
prefLabel
Pharmacogenetics of cancer therapy: getting personal
@ast
Pharmacogenetics of cancer therapy: getting personal
@en
Pharmacogenetics of cancer therapy: getting personal
@nl
P2860
P356
P1476
Pharmacogenetics of cancer therapy: getting personal
@en
P2093
E Y Krynetski
P2860
P356
10.1086/301941
P407
P577
1998-07-01T00:00:00Z